Dr. Jason Mouabbi & Dr. Paolo Tarantino - T-Dxd, HER2 Low & The Future of Breast Cancer Treatment

In this episode of CHM Conversations, two of breast oncology’s brightest specialists — Dr. Jason Mouabbi and Dr. Paolo Tarantino — explore how trastuzumab deruxtecan (T-DXd) has fundamentally restructured therapeutic strategies across HER2-positive and HER2-low disease, while “curing” what was once thought to be really aggressive disease. From the transformative DESTINY-Breast trials to the evolving art of real-world clinical decision-making, they dissect not only the science and trial data but the shifting frameworks now guiding oncologists at the bedside.They critically examine how T-DXd, once a remarkable agent for refractory HER2+ tumors, is now reshaping standards in HER2-low and ultra-low settings, overcoming historical binaries of HER2 classification. Their conversation traverses management of brain metastases, individualized sequencing to mitigate ILD risks, and emerging strategies to move away from indefinite therapy models. Importantly, they emphasize the growing need for precision-driven, patient-centered oncology at a time when therapeutic options are expanding faster than rigid guidelines can adapt.Whether you're a healthcare provider, researcher, or patient advocate, this is a must-listen episode that offers deep insight into one of the most promising advances in breast cancer therapy.🔬 Topics include:• The T-DXd era: from preclinical promise to clinical breakthrough• Reframing HER2 biology: Low and ultra-low as therapeutic targets, not distinct entities• Management of brain metastases• Strategic dominance in metastatic disease: DESTINY-Breast03, 04, 06, and 12 insights• Sequencing treatment strategies and minimizing ILD risk• Minimizing ILD risk: The Five S's — Screen, Scan, Synergy, Suspend, Steroids• The future of early-stage disease: Neoadjuvant and adjuvant trials challenging classical chemotherapy models🎧 Don’t forget to like, share, and subscribe for more CHM Conversations#BreastCancer #OncologyPodcast #TDXd #HER2Low #CHMConversations #PrecisionMedicine #CancerResearch–Thanks for listening!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media